Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir


  • Potential conflict of interest: V.L.R.: Speaking and Teaching: Roche, Schering-Plough MSD, Janssen, Bristol-Myers Squibb, Gilead; Grant/Research Support: Roche, Bristol-Myers Squibb; Board Membership: Gilead, Roche. P.C.: none. C.V.: none. M.E.: Speaking and Teaching: Bristol-Myers Squibb, Gilead. Board Membership: Gilead.

No abstract is available for this article.